BIOTRICITY INC

For the period ended Mar 31, 2024. Filed Jun 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Jun 27, 2024

BTCY$0.06+7.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	Year Ended March 31, 2024	Year Ended March 31, 2023
	$	$
REVENUE	12,063,345	9,639,057
Cost of Revenue	3,707,064	4,197,024
GROSS PROFIT	8,356,281	5,442,033
EXPENSES
Selling, general and administrative expenses	14,612,724	17,621,865
Research and development expenses	2,571,826	3,229,879
TOTAL OPERATING EXPENSES	17,184,550	20,851,744
LOSS FROM OPERATIONS	(8,828,269)	(15,409,711)
Other income/(expense) [Notes 3, 5]	(102,607)	(110,822)
Interest expense [Notes 5, 6, 7]	(3,018,803)	(1,839,159)
Gain/(Loss) upon convertible promissory notes conversion and redemption [Note 5]	18,539	(71,119)
Accretion and amortization expenses [Notes 5, 6]	(2,172,920)	(743,459)
Change in fair value of derivative liabilities [Note 8]	9,777	(483,873)
NET LOSS BEFORE INCOME TAXES	(14,094,283)	(18,658,143)
Income taxes [Note 10]	—	—
NET LOSS BEFORE DIVIDENDS	(14,094,283)	(18,658,143)
Preferred Stock Dividends	(834,677)	(875,540)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(14,928,960)	(19,533,683)
Translation adjustment	185,175	615,859
COMPREHENSIVE LOSS	(14,743,785)	(18,917,824)
LOSS PER SHARE, BASIC AND DILUTED	(1.660)	(2.256)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	8,991,766	8,659,718

BIOTRICITY, INC.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.